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Abstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used despite their risk of gastrointestinal
bleeding or cardiovascular events. We report the profile of people taking NSAIDs in Spain, and we include
demographic factors, health-related behaviours and cardiovascular disease history.
Methods: Four thousand sixtyparticipants were selected using a pseudorandom number list from Family Practice
lists in 12 Spanish provinces. They completed a face-to-face computerized interview on their NSAID consumption,
demographic characteristics, body mass index, alcohol and tobacco consumption and medical history. In addition,
participants completed a self-administered food-frequency and alcohol consumption questionnaire. Factors
associated with ever and current NSAID consumption were identified by logistic regression.
Results: Women consumed more non-aspirin NSAIDs (38.8% [36.7–41.0]) than men (22.3 [20.5–24.2]), but men
consumed more aspirin (11.7% [10.3–13.2]) than women (5.2% [4.3–6.3]). Consumption of non-aspirin NSAIDs decrease
with age from 44.2% (39.4–49.1) in younger than 45 to 21.1% (18.3–24.2) in older than 75, but the age-pattern for
aspirin usage was the opposite. Aspirin was reported by about 11% patients, as being twice as used in men (11.7%)
than in women (5.2%); its consumption increased with age from 1.7% (< 45 years old) to 12.4% (≥75 years old). Aspirin
was strongly associated with the presence of cardiovascular risk factors or established cardiovascular disease, reaching
odds ratios of 15.2 (7.4–31.2) in women with acute coronary syndrome, 13.3 (6.2–28.3) in women with strokes and 11.1
(7.8–15.9) in men with acute coronary syndrome. Participants with cardiovascular risk factors or diseases consumed as
much non-aspirin NSAID as participants without such conditions.
Conclusions: Non-aspirin NSAIDs were more consumed by women and aspirin by men. The age patterns of aspirin
and non-aspirin NSAIDs were opposite: the higher the age, the lower the non-aspirin NSAIDs usage and the higher the
aspirin consumption. People with cardiovascular risk factors or diseases consumed more aspirin, but they did not
decrease their non-aspirin NSAIDs usage.
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Background
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of
the most used therapeutic groups of agents; they can be ob-
tained over-the-counter in many countries, and they are
used for a wide variety of indications, including short-term
and long-term treatment of pain, traumatisms, inflammatory
diseases such as arthritis, rheumatoid arthritis and many
others. On the other hand, NSAIDs can be responsible for
several well-known side effects, comprising upper gastro-
intestinal bleeding [1] and cardiovascular disease [2]. While
gastrointestinal haemorrhage would partially be prevented
by adding proton-pump inhibitors to NSAIDs [3, 4], there is
still some controversy regarding the differences in cardiovas-
cular risk among the NSAID family [5].
Although the consumption of NSAIDs in Spain has de-
creased from 43.1 in the year 2013 to 37.9 in 2016, and this
decrease in consumption was observed in all subgroups [6];
some studies have shown a trend towards increasing
NSAID usage in developed countries [7, 8]. Little is known,
however, about the medical characteristics of the con-
sumers. In this way, medical records would be insufficient
to establish patient profile, as a relevant NSAID amount is
traded over-the-counter. Demographic characteristics are
associated with different adverse effect risks. For instance,
gastrointestinal haemorrhage is more frequent in elder
people taking NSAIDs than in youngsters [1], and similar
considerations could are responsible for cardiovascular ef-
fects [2]. Moreover, some health-related behaviours, such as
alcohol [9] or -we speculate- tobacco usage, if associated
with NSAID consumption, could potentiate their risk of
cardiovascular episodes or gastrointestinal bleeding. Thus,
Chi et al. observed that the proportions of patients with
concomitant antiplatelet drugs, H pylori infection and sta-
tus of smoking were also considerably higher in GI (gastro-
intestinal) bleeding group compared to non-GI bleeding
group GI bleeding group associated with NSAIDs drugs
[10] and Sostres et al. also observed that a higher risk of
upper GI bleeding was associated with current or past
smoking habit and previous history of peptic ulcer [11].
The aim of this study is to describe demographic char-
acteristics related to NSAID consumption in the adult
population in Spain, as well as health-related behaviors
and cardiovascular risk factors. In order to do this, we
analysed the control sample (about 4000 subjects) in the
MCC-Spain project, a multi-centre case-control study
carried out in Spain.
Methods
MCC-Spain is a case-control study on cancer carried out in
12 Spanish provinces: Asturias, Barcelona, Cantabria, Gi-
rona, Granada, Gipuzkoa, Huelva, León, Madrid, Murcia,
Navarra, and Valencia [12]. More than 10,000 patients were
recruited from 2009 to 2012, including cases of colorectal,
breast, prostate or gastric cancer, and chronic lymphoid
leukaemia, and 4062 controls frequency matched by age, sex
and area of recruitment. In this article, only the control sam-
ple will be analysed, so all references to patients, subjects or
participants from here on refer to the control sample. The
study design, sample size and data gathering were planned
for the case-control study.
Participants were recruited using computer-generated
pseudorandom numbers from the list of patients assigned
to general practice clinics. Selected people were contacted
by phone; if contact with the selected person was not pos-
sible after a minimum of five tries at different times of the
day, or if he/she refused to participate, the following person
on the list was approached. In the Spanish Health System,
every inhabitant is assigned to a general practice clinic irre-
spective of whether he or she does attend to that clinic;
therefore, selecting by random from those lists did not
introduce a bias towards sick people. Participants who
agreed to partake in the study signed an informed consent
before the face-to-face interview, and the protocol of
MCC-Spain was approved by the local Ethics Committees
of participating institutions (Comité Ético de Investigación
Clínica (CEIC) del Instituto Municipal de Asistencia Sani-
taria de Barcelona; CEIC del Hospital Universitario de Bell-
vitge; CEIC de Navarra; CEIC del Hospital Universitario La
Paz; CEIC del Hospital Universitario Ramón y Cajal; CEIC
de Cantabria; CEIC de Gipuzkoa; CEIC de Girona; Comité
de Ética de la Investigación de la Provincia de Huelva; CEIC
de León; Comité Ético de Investigación del Principado de
Asturias), in conformity to the principles of the Declaration
of Helsinki. The database was registered in the Spanish
Agency for Data Protection (no. 2102672171).
A structured computerized epidemiological questionnaire
was administered by trained personnel in a face-to-face
interview to get information on demographics, anthropo-
metrics, family history of cancer, history of diseases, drug
consumption, occupational history, health behaviours, and
reproductive factors [13]. Usage of NSAIDs was specifically
asked about using a detailed questionnaire including the
specific NSAID, age at beginning, age when end duration of
consumption and current consumption; a participant was
considered as having taken a specific NSAID if she/he
reported to have taken at least 30 doses. We carried out sep-
arated analyses for ever and current consumers of NSAIDs;
current consumption could be consequence of recent
conditions, while ever consumption better represents
cumulative exposure to NSAIDs but it could be more
prone to recall bias.
On the other hand, participants were provided with a
semi-quantitative Food Frequency Questionnaire (FFQ) pre-
viously validated in the Spanish population [14], which
included questions on alcohol consumption both currently
and at 30–40 years old [15]. The FFQ was self-administered
and returned by mail or filled out face to face within a
period not exceeding 15 days after the interview [13]. Only
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3509 participants answered this questionnaire. Alcohol
consumption was asked for every type of beverage; for in-
stance, we asked “How often do you drink one glass of red
wine?”, giving the options: never or less than 1 time per
month / 1–3 per month / 1–2 per week / 3–4 per week /
5–6 per week / 1 per day / 2–3 per day / 2–3 per day / 4
or more per day. Then we assumed a glass of wine being
100 cL, containing 12% alcohol. Average alcohol drinking
was classified in abstainer (less than one drink per month),
category I (0–19.9 g /day for women and 0–39.9 g/day for
men), category II (20–39.9 g/day for women, 40–59.9 g/
day for men) and category III (≥40 g/day for women,
≥60 g/day for men), according to the comparative risk as-
sessment module of the Global Burden of Disease [16].
For instance, it would be necessary to take 4 glasses of
wine or 2 cups of whisky to reach 40 g of alcohol. NSAIDs
were classified according to the Anatomical and Thera-
peutic Classification of Drugs (ATC) in aspirin (ATC code
N02BA01), butilpirazone (M01aa), acetic derivatives
(M01ab), oxicams (M01 ac), propionates (M01ae), coxibs
(M01ah) and others (M01ax).
A separated analysis was carried out to ascertain
NSAID consumption in people with cardiovascular dis-
eases or risk factors, as current clinical guidelines point
out the increase of cardiovascular risk associated with
non-aspirin NSAIDs.
Proportions and their 95% confidence intervals (CI)
were estimated assuming a binomial distribution. Vari-
ables associated with NSAID consumption were identi-
fied by binomial logistic regression; its results are
displayed as odds ratios (OR) with 95% CI. The statis-
tical package Stata 14/SE was used for the analysis (Stata
Corp, College Station, Tx, US).
Results
Characteristics of the 4060 controls included in this ana-
lysis are reported in Table 1. They were 2023 women and
2037 men, with ages ranging 22–85; 49.4% had reached
secondary or university education. 61.8% subjects were
overweight or obese, 19.2% were current smokers and,
when being 30–40 years old, 16% had an average alcohol
consumption higher than 20 g/day in women and 40 g/
day in men. About one participant in four suffered arth-
ritis, 10% had chronic cephalalgia and 5.6%, gout. Arthritis
and chronic cephalalgia were more frequent in women.
Figure 1 and Additional file 1 reported the ever NSAID
consumption frequency by age and sex. About 30% subjects
reported non-aspirin NSAID consumption, showing a
step-down trend with age, from 44.2% in subjects under 45
to 21.1% in patients over 75. Women consumed NSAID at
higher rates than men (38.8% vs. 22.3%); this gender pattern
was consistent among all ages. The most consumed NSAID
group was propionates (M01ae) (29.2%) with, again, a con-
sistent age and sex pattern: higher consumption in women
and in youngsters. Aspirin was reported by about 11% pa-
tients, being twice as used in men (11.7%) than in
women (5.2%); its consumption increased with age
from 1.7% (< 45 years old) to 12.4% (≥75 years old).
Acetate derivatives (M01ab) -the third most con-
sumed group- was reported in similar percentages by
both sexes, without a neat trend with age. Consump-
tion of the remaining groups was scarce (butylpyrazo-
lidines (M01aa): 0.03%, oxicam (M01 ac): 0.6%, coxib
(M01ah): 0.6%, others (M01ax): 2.19%) and we did
not carry out additional analyses on them. Consump-
tion of NSAIDs at the time of recruitment is reported in
Fig. 2 and Additional file 2. Women used non-aspirin
NSAIDs twice as much as men (20.7% for women vs. 9.0%
for men); again, this pattern was consistent across age
groups, with non-aspirin NSAID consumption decreasing
from 22.1% in younger than 45 years to 10.4% in older than
75. Aspirin, however, was more consumed by men (9.0%)
than for women (2.9%) and its rates increased with age in
both men and women. About two thirds of the non-aspirin
NSAID consumption was due to propionates; in men, the
consumption declined from 9.4% in younger than 45 years
old to 2.7% in men older than 75; in women, the decrease
was from 20.7% (< 45 years) to 9.4% (> 75 years).
Consumption by province (Additional file 3) was het-
erogeneous ranging from 13.4% (in Granada) to 45.1% in
Girona) for non-aspirin NSAIDs.
The most frequently ever used specific NSAIDs were
ibuprofen (20.4%), aspirin (11%) and diclofenac (6.4%).
Only three other drugs were used by more than 1% of
people: aciclofenac (1.5%), naproxen (1.4%) and chon-
droitin sulphate (1.3%). Regarding current consumption,
only ibuprofen (9.2%), aspirin (5.9%), diclofenac (2.0%)
and chondroitin sulphate (1.0%) reached the 1% cut off
(Additional file 4).
Factors related to NSAIDs ever consumption
Tables 2, 3, 4 and 5 report the factors associated with con-
sumption of the main NSAID groups in men and women,
according to the multivariate logistic regression analysis.
Non-aspirin NSAID were less consumed in men as age in-
creased (reaching OR= 0.26 in men older than 75 compared
to men between 45 and 54 years old) and as education level
goes up, being about twice as frequent in men with univer-
sity level than in men without primary studies; no associ-
ation was found among non-aspirin NSAID consumption in
men and body mass index (BMI)or ethanol consumption.
However, men who currently use NSAIDs that are not
aspirin were half less likely (OR = 0.49) to be current
smokers than non-smokers. If we consider chronic disease
involving pain, men who had arthritis multiplied by almost
3 the probability of taking non-aspirin NSAID and doubled
its use in other chronic disease involving pain that were not
arthritis gout or chronic cephalalgia (Table 2). Similar
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Table 1 Descriptive analysis of sociodemographic variables
Variable Category Total Women
(N = 2023, 49.8%)
Men
(N = 2037, 50.2%)
Frequency (%)
or MEAN ± SD
Frequency (%)
or MEAN ± SD
Frequency (%)
or MEAN ± SD
Age (years) Continuous 62.9 ± 12.1 59.3 ± 13.3 66.5 ± 9.6
Age (years) 22–44 421 (10.4) 357 (17.7) 64 (3.1)
45–54 579 (14.3) 428 (21.2) 151 (7.4)
55–64 1013 (25.0) 444 (22.0) 569 (27.9)
65–74 1278 (31.5) 476 (23.5) 803 (39.4)
75–85 769 (18.9) 318 (15.7) 452 (22.2)
Education level Lower than primary 755 (18.6) 372 (18.4) 383 (18.8)
Primary education 1301 (32.0) 616 (30.5) 686 (33.6)
Secondary education 1172 (28.9) 616 (30.5) 556 (27.3)
University 832 (20.5) 419 (20.7) 414 (20.3)
Body mass index (kg/m2) < 18.5 54 (1.3) 45 (2.29 9 (0.4)
18.5–24.9 1498 (36.9) 946 (46.8) 553 (27.1)
25–29.9 (overweight) 1661 (40.9) 640 (31.6) 1022 (50.1)
≥30 (obesity) 847 (20.9) 392 (19.4) 455 (22.3)
Smoking No smoker 1812 (44.6) 1236 (61.1) 576 (28.3)
Current smoker 780 (19.2) 375 (18.5) 405 (19.9)
Former smoker 1468 (36.2) 1057 (51.8) 411 (20.4)
Alcohol consumption at recruitment
(g/day)
Abstainers 939 (26.8) 637 (37.0) 302 (16.9)
0–19.9 (women), 0–39.9 (men) 2295 (65.4) 999 (58.1) 1296 (72.4)
20–39.9 (women), 40–59.9 (men) 203 (5.8) 74 (4.3) 129 (7.2)
≥40 (women), ≥60 (men) 72 (2.0) 9 (0.5) 63 (3.5)
Alcohol consumption when
30–40 years old (g/day)
0 903 (25.7) 657 (38.3) 246 (13.7)
0–19.9 (women), 0–39.9 (men) 2047 (58.3) 951 (55.3) 1096 (61.2)
20–39.9 (women), 40–59.9 (men) 300 (8.6) 86 (5.0) 214 (12.0)
≥40 (women), ≥60 (men) 259 (7.4) 24 (1.4) 235 (13.1)
Number of births(women) 0 375 (18.5)
1–2 1085 (53.6)
> 2 563 (27.9)
Menopausal status (women) Premenopausal 650 (32.1)
Postmenopausal 1373 (67.9)
Chronic disease involving pain Arthritis 1005 (24.9) 626 (31.1) 379 (18.7)
Gout 225 (5.6) 24 (1.2) 201 (9.9)
Chronic cephalalgia 414 (10.2) 307 (15.3) 107 (5.3)
Arthritis, gout or chronic cephalalgia 1425 (35.1) 816 (40.3) 609 (29.9)
Cardiovascular disease or risk
factor
Diabetes mellitus 594 (14.7) 191 (9.5) 403 (19.8)
Hypertension 1513 (37.4) 587 (29.2) 926 (45.6)
Hypercholesterolemia 1344 (33.3) 580 (28.9) 764 (37.7)
Acute coronary syndrome 312 (7.7) 58 (2.9) 254 (12.5)
Stroke 151 (3.7) 53 (2.6) 94 (4.8)
Other circulatory diseases 628 (15.5) 330 (16.4) 298 (14.7)
Gómez-Acebo et al. BMC Public Health  (2018) 18:1134 Page 4 of 13
patterns were found in women, although both age and edu-
cation levels showed less apparent trends. Number of births
and menopausal status were not associated with non-aspirin
NSAIDs consumption. Patients with chronic conditions in-
volving pain (arthritis, gout or chronic cephalalgia) con-
sumed non-aspirin NSAIDs four times as much as
participants without such conditions. In contrast than men,
women who once used NSAIDs without aspirin were ap-
proximately 38% more likely to be current smokers than
nonsmokers and use in chronic cephalalgia (OR 2.54 for
ever or OR 1.66 for current use).
As propionate derivatives were the more frequently
consumed NSAID group, its related factors (Table 3) re-
sembled those of non-aspirin NSAIDs: the higher the
age, the lower the propionate derivative consumption,
and for men, the higher the education level, the higher
their propionate derivative consumption. People with
conditions with chronic pain (arthritis, chronic cephalal-
gia or gout) used propionate derivates twice or three
times more frequently than people without such condi-
tions. Multivariate results in aspirin consumptions are
displayed in Table 4. Men increased their aspirin con-
sumption with age, being about three times higher in
men older than 65, and smoking habit, with current or
former smokers having 60% higher aspirin consumption
than non-smoking men. In women, however, only age
and number of births (OR = 1.24 for each birth) in-
creased aspirin consumption.
Factors associated with acetate derivates are analyzed
in Table 5. Chronic diseases involving pain multiplied by
2.7 (women) and 3.5 (men) the odds of having used acet-
ate derivates. Apart from this factor, in men, only the
Fig. 1 Anytime consumption of NSAID by age and sex. 1a: Aspirin and non-aspirin NSAID. 1b: Propionates and acetate derivates
Fig. 2 Current consumption of NSAID by age and sex. 1a: Aspirin and non-aspirin NSAID. 1b: Propionates and acetate derivates
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educational level reached a positive significant relationship
with consumption; men with secondary or university edu-
cation reported about twice the acetate derivative con-
sumption than men with lower educational levels. No other
factor can be identified as associated with acetate derivative
consumption in women. BMI displayed a non-significant
association in both men and women.
Factors related to current consumption
Non-aspirin NSAIDs consumption (Table 2) stepped down
with age in both women (OR= 1.17, 1, 0.62, 0.39 and 0.46
for the ordered age groups) and men (OR= 1.57, 1, 1.27,
0.76 and 0.37). Men with university level education
consumed twice as much as men with less-than-primary
level; a similar result was not found in women. Consump-
tion of non-aspirin NSAIDs was halved in current smoking
men. Regarding alcohol use, only participants in the highest
category of current consumption (i.e.: ≥60 g/day for men
and ≥ 40 g/day for women) reported higher non-aspirin
NSAID used, although estimates were unstable for women
due to the small number of women in this category. Suffer-
ing arthritis, gout or chronic cephalalgia multiplies the prob-
ability of using non-aspirin NSAIDs by about 4.
Propionates consumption (Table 3) in men went down
with age -reaching OR = 0.19 in men older than 75- and
in current smokers (OR = 0.55). Suffering chronic pain
Table 2 Factors associated with non-aspirin NSAID consumption: odds ratios and 95% confidence intervals adjusted for the
remaining factors in the table and province of recruitment
Variable Category Ever consumption Current consumption
Women Men Women Men
Age < 45 1.50 (1.04–2.15) 1.23 (0.62–2.44) 1.17 (0.78–1.75) 1.57 (0.56–4.42)
45–54 1 (ref) 1 (ref) 1 (ref) 1 (ref)
55–64 0.58 (0.40–0.85) 0.53 (0.34–0.83) 0.62 (0.41–0.96) 1.27 (0.63–2.55)
65–74 0.39 (0.26–0.59) 0.45 (0.29–0.70) 0.39 (0.24–0.62) 0.76 (0.38–1.54)
≥75 0.39 (0.24–0.62) 0.26 (0.16–0.43) 0.46 (0.27 (0.78) 0.37 (0.17–0.84)
BMI < 18.5 1.06 (0.53–2.15) 1.75 (0.23–13.6) 0.39 (0.14–1.07) 3.50 (0.28–44.3)
18.5–24.9 1 (ref) 1 (ref) 1 (ref) 1 (ref)
25–29.9 0.94 (0.73–1.21) 0.99 (0.74–1.32) 0.94 (0.70–1.27) 0.90 (0.60–1.37)
≥30 1.38 (1.02–1.88) 0.85 (0.59–1.22) 1.30 (0.92–1.84) 1.06 (0.65–1.74)
Education Less than primary 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Primary education 1.31 (0.92–1.85) 1.56 (1.04–2.33) 0.91 (0.61–1.36) 1.11 (0.63–1.98)
Secondary education 1.21 (0.83–1.76) 2.10 (1.39–3.16) 0.90 (0.58–1.39) 1.30 (0.72–2.33)
University 1.70 (1.12–2.58) 2.55 (1.65–3.95) 1.29 (0.80–2.07) 2.12 (1.15–3.89)
No. of births (by each birth) 1.04 (0.97–1.12) 1.05 (0.96–1.14)
Premenopause (ref.: postmenopause) 0.86 (0.61–1.22) 1.15 (0.77–1.70)
Smoking No smoker 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Former smoker 1.20 (0.90–1.59) 1.03 (0.77–1.36) 1.00 (0.72–1.39) 0.98 (0.66–1.45)
Current smoker 1.38 (1.02–1.88) 0.76 (0.52–1.09) 1.07 (0.76–1.53) 0.49 (0.27–0.88)
Alcohol consumption at recruitment (g/day)
Abstainers 1 (ref) 1 (ref) 1 (ref) 1 (ref)
0–39.9 (men), 0–19.9 (women) 1.03 (0.76–1.39) 1.26 (0.85–1.88) 0.78 (0.55–1.11) 1.06 (0.58–1.92)
40–59.9 (men), 20–39.9 (women 1.11 (0.57–2.14) 1.60 (0.89–2.89) 0.58 (0.25–1.30) 1.16 (0.49–2.79)
≥ 60 g/day (men), ≥40 g/day (women) 1.22 (0.26–5.68) 1.95 (0.94–4.02) 3.03 (0.56–16.6) 2.69 (0.97–7.44)
Alcohol when 30–40 years old
Abstainers 1 (ref) 1 (ref) 1 (ref) 1 (ref)
0–39.9 (men), 0–19.9 (women) 1.01 (0.75–1.36) 0.94 (0.62–1.42) 1.30 (0.92–1.84) 1.88 (0.96–3.68)
40–59.9 (men), 20–39.9 (women 1.28 (0.69–2.36) 1.08 (0.64–1.82) 1.93 (0.95–3.93) 2.11 (0.94–4.72)
≥ 60 g/day (men), ≥40 g/day (women) 0.97 (0.37–2.58) 0.81 (0.48–1.36) 1.42 (0.45–4.47) 0.78 (0.32–1.87)
Chronic disease involving pain
Yes (ref: No) 4.31 (3.37–5.50) 3.60 (2.78–4.67) 3.77 (2.85–4.99) 4.59 (3.18–6.61)
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conditions (OR= 2.48) and having reached university level
(OR = 2.00) were the only factors associated with higher
propionate used. In women, higher ages were also associated
with lower propionate consumption (OR= 0.38 in women
> 75 years) and the presence of chronic pain diseases, with
higher consumption (OR= 2.58); no other factor could be
identified as associated with this NSAID group.
Higher age was a risk factor for using aspirin in both
women and men (Table 4), with OR for the elder group
reaching 6.8 (women) and 4.7 (men). The education
level was negatively associated with aspirin consumption
in women, but not in men, while smokers (both former
and current) were related with higher aspirin use in
men. Suffering from a chronic pain condition was not
associated with aspirin consumption.
Apart from chronic pain diseases, which were associ-
ated with 3 or 4 times higher acetate derivate consump-
tion (Table 5), only non-significant positive associations
were found between this NSAID group and alcohol
consumption (both sexes) and higher education level
(men, but not women).
NSAID consumption and cardiovascular disease or risk
factors
To further explore the risk profile of cardiovascular ad-
verse events while taking NSAIDs, we analysed the
Table 3 Factors associated with propionate derivate consumption: odds ratios and 95% confidence intervals adjusted for the
remaining factors in the table and province of recruitment
Variable Category Ever consumption Current consumption
Women Men Women Men
Age < 45 1.47 (1.02–2.12) 1.48 (0.73–3.00) 1.17 (0.76–1.79) 1.33 (0.45–3.94)
45–54 1 (ref) 1 (ref) 1 (ref) 1 (ref)
55–64 0.54 (0.36–0.80) 0.45 (0.28–0.73) 0.72 (0.45–1.16) 0.85 (0.41–1.76)
65–74 0.32 (0.21–0.49) 0.40 (0.25–0.65) 0.36 (0.21–0.62) 0.57 (0.27–1.19)
≥75 0.30 (0.18–0.51) 0.20 (0.11–0.35) 0.38 (0.20–0.71) 0.19 (0.07–0.50)
BMI < 18.5 1.46 (0.72–2.98) 0.98 (0.10–10.1) 0.33 (0.09–1.13) –
18.5–24.9 1 (ref) 1 (ref) 1 (ref) 1 (ref)
25–29.9 0.81 (0.61–1.07) 0.98 (0.71–1.36) 0.94 (0.67–1.31) 0.98 (0.60–1.62)
≥30 1.38 (1.00–1.90) 0.81 (0.54–1.23) 1.35 (0.92–1.98) 1.33 (0.75–2.39)
Education Less than primary 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Primary education 1.30 (0.89–1.90) 1.83 (1.13–2.96) 0.91 (0.57–1.45) 1.27 (0.63–2.56)
Secondary education 1.15 (0.76–1.74) 2.17 (1.33–3.55) 0.82 (0.49–1.35) 1.27 (0.63–2.56)
University 1.42 (0.90–2.23) 2.57 (1.53–4.33) 1.00 (0.58–1.72) 2.00 (0.95–4.24)
No. of births (by each birth) 1.08 (0.99–1.17) 1.01 (0.91–1.12) –
Premenopause (ref.: postmenopause) 1.16 (0.80–1.67) 1.57 (1.02–2.43) –
Smoking No smoker 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Former smoker 1.09 (0.81–1.48) 1.05 (0.76–1.46) 1.01 (0.70–1.46) 0.95 (0.60–1.51)
Current smoker 1.13 (0.82–1.56) 0.74 (0.48–1.14) 1.10 (0.75–1.62) 0.55 (0.28–1.08)
Alcohol consumption at recruitment (g/day)
Abstainers 1 (ref) 1 (ref) 1 (ref) 1 (ref)
0–39.9 (men), 0–19.9 (women) 1.22 (0.89–1.68) 1.06 (0.67–1.66) 0.75 (0.51–1.10) 0.91 (0.47–1.77)
40–59.9 (men), 20–39.9 (women) 1.41 (0.69–2.87) 1.10 (0.55–2.19) 0.58 (0.22–1.52) 0.98 (0.35–4.48)
≥ 60 g/day (men), ≥40 g/day (women) 0.50 (0.05–4.80) 1.48 (0.64–3.39) 0.98 (0.09–10.9) 1.25 (0.35–4.48)
Alcohol when 30–40 years old
Abstainers 1 (ref) 1 (ref) 1 (ref) 1 (ref)
0–39.9 (men), 0–19.9 (women) 0.86 (0.63–1.18) 1.22 (0.76–1.96) 1.19 (0.81–1.75) 1.10 (0.54–2.23)
40–59.9 (men), 20–39.9 (women) 0.79 (0.40–1.54) 1.15 (0.63–2.12) 1.29 (0.55–3.01) 1.26 (0.52–3.06)
≥ 60 g/day (men), ≥40 g/day (women) 0.55 (0.17–1.75) 0.94 (0.51–1.73) 0.60 (0.12–3.11) 0.62 (0.24–1.63)
Chronic disease involving pain
Yes (ref: No) 3.08 (2.37–3.99) 2.22 (1.65–2.98) 2.58 (1.89–3.52) 2.48 (1.61–3.82)
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relationship between NSAID use and current cardiovascu-
lar disease or risk factors. Results are shown in Table 6.
Men with diabetes mellitus consumed less non-aspirin
NSAIDs -and, specifically, less propionates- than men
without that condition; no such result could be
found for women. Having hypertension, hypercholes-
terolemia or medical history of acute coronary syn-
drome (i.e.: acute myocardial infarction or angina),
stroke or other circulatory diseases was not associ-
ated with lower non-aspirin NSAID consumption in
any gender. Using aspirin, however, increased in
both women and men suffering any of these cardio-
vascular risk factors or diseases, with OR as higher
as 15.2 (women with acute coronary syndrome), 13.3
(women having had a stroke) or 11.1 (men with
acute coronary syndrome).
Discussion
According to our results, NSAID consumption differed
by gender and age, being aspirin more used by men and
older participants and propionates by women and the
youngsters. Consumption of any major NSAID group
was consistently associated with educational level in
men: the higher the educational level, the higher the
NSAID usage. Regarding health-related behaviours,
current smoker women had ever consumed more
Table 4 Factors associated with aspirin consumption: odds ratios and 95% confidence intervals adjusted for the remaining factors in
the table and province of recruitment
Variable Category Ever consumption Current consumption
Women Men Women Men
Age < 45 0.62 (0.20–1.96) 0.25 (0.03–2.06) 0.76 (0.06–9.39) –
45–54 1 (ref) 1 (ref) 1 (ref) 1 (ref)
55–64 2.03 (0.81–5.13) 1.54 (0.70–3.40) 2.99 (0.57–15.7) 2.35 (0.81–6.84)
65–74 2.26 (0.85–6.01) 2.41 (1.12–5.19) 4.90 (0.91–26.3) 3.99 (1.41–11.3)
≥75 3.59 (1.26–10.2) 3.09 (1.39–6.87) 6.83 (1.21–38.7) 4.74 (1.62–13.9)
BMI < 18.5 1.77 (0.37–8.38) – 2.01 (0.24–17.1) –
18.5–24.9 1 (ref) 1 (ref) 1 (ref) 1 (ref)
25–29.9 0.75 (0.41–1.36) 1.02 (0.70–1.47) 0.68 (0.31–1.53) 2.35 (0.81–6.84)
≥30 1.73 (0.98–3.07) 1.32 (0.85–2.04) 1.42 (0.66–3.05) 1.45 (0.89–2.38)
Education Less than primary 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Primary education 0.77 (0.41–1.45) 1.43 (0.90–2.27) 0.62 (0.29–1.30) 1.23 (0.75–2.02)
Secondary education 0.84 (0.42–1.71) 1.60 (0.98–2.61) 0.34 (0.12–0.94) 1.35 (0.79–2.29)
University 0.87 (0.38–2.05) 1.56 (0.92–2.65) 0.16 (0.03–0.80) 1.22 (0.68–2.19)
No. of births (by each birth) 1.25 (1.09–1.42) 1.15 (0.97–1.36) –
Premenopause (ref.: postmenopause) 1.21 (0.50–2.93) 0.72 (0.19–2.75) –
Smoking No smoker 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Former smoker 1.33 (0.69–2.58) 1.67 (1.14–2.44) 1.00 (0.36–2.80) 1.80 (1.16–2.79)
Current smoker 1.89 (0.96–3.71) 1.64 (1.01–2.64) 1.71 (0.63–4.65) 1.85 (1.07–3.19)
Alcohol consumption at recruitment (g/day)
Abstainers 1 (ref) 1 (ref) 1 (ref) 1 (ref)
0–39.9 (men), 0–19.9 (women) 1.14 (0.62–2.08) 0.81 (0.52–1.27) 1.19 (0.54–2.65) 0.96 (0.58–1.60)
40–59.9 (men), 20–39.9 (women) 0.64 (0.15–2.69) 0.49 (0.22–1.09) 1.05 (0.16–6.98) 0.52 (0.21–1.33)
≥ 60 g/day (men), ≥40 g/day (women) NA 1.01 (0.41–2.46) – 1.38 (0.52–3.65)
Alcohol when 30–40 years old
Abstainers 1 (ref) 1 (ref) 1 (ref) 1 (ref)
0–39.9 (men), 0–19.9 (women) 1.00 (0.55–1.83) 1.73 (1.00–3.00) 1.08 (0.49–2.40) 1.40 (0.77–2.53)
40–59.9 (men), 20–39.9 (women) 2.16 (0.75–6.26) 1.44 (0.72–2.89) 2.61 (0.62–10.9) 1.13 (0.52–2.45)
≥ 60 g/day (men), ≥40 g/day (women) NA 1.44 (0.74–2.78) – 1.23 (0.60–2.53)
Chronic disease involving pain
Yes (ref: No) 1.27 (0.78–2.08) 1.23 (0.89–1.70) 0.71 (0.36–1.36) 1.10 (0.76–1.59)
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non-aspirin NSAIDs but current smoker men had lower
current consumption of non-aspirin NSAIDs than no
smoker women and men, respectively. Higher current
consumption was found in current heavy ethanol
drinkers. People with higher risk of cardiovascular ad-
verse episodes when taking non-aspirin NSAIDs (i.e.:
participants with cardiovascular disease history or car-
diovascular risk factors) consumed as much non-aspirin
NSAID as people without such a high risk, the only ex-
ception being men with diabetes mellitus, who halved
the non-aspirin NSAID current consumption. Nonethe-
less, participants with higher cardiovascular risk took as-
pirin more frequently.
Consumption compared with other countries
Ibuprofen was by far the more consumed NSAID in our
study. Higher use of ibuprofen has also been informed
in Germany [17], the US [18] and Denmark [19]. A
study on 15 countries, however, reported diclofenac as
the most frequently used, followed by ibuprofen [20].
Many articles have reported NSAID trend use [17, 21],
which has not been analysed in our study. However, the
trend in Spain seemed to be rising until 2009 and slowly
decreasing from then on; specifically, ibuprofen reaching
its zenith in 2009, while naproxen began to increase in
2012 [22]. Qato et al. [7] informed of increases in
NSAID drugs from 2005 to 2011 in the US, with aspirin
Table 5 Factors associated with acetate acid derivate consumption: odds ratios and 95% confidence intervals adjusted for the
remaining factors in the table and province of recruitment
Variable Category Ever consumption Current consumption
Women Men Women Men
Age < 45 1.12 (0.51–2.43) 0.76 (0.22–2.59) 0.86 (0.26–2.81) 2.88 (0.39–21.2)
45–54 1.00 (ref) 1 (ref) 1 (ref) 1 (ref)
55–64 0.86 (0.47–1.55) 0.58 (0.28–1.19) 0.73 (0.29–1.84) 1.44 (0.33–6.27)
65–74 0.66 (0.34–1.26) 0.52 (0.26–1.06) 0.52 (0.18–1.45) 0.96 (0.22–4.19)
≥75 0.81 (0.39–1.68) 0.48 (0.22–1.06) 0.73 (0.24–2.24) 1.20 (0.25–5.62)
BMI < 18.5 0.27 (0.03–2.13) 2.62 (0.17–40.8) 0.78 (0.09–6.66) –
18.5–24.9 1.00 (ref) 1 (ref) 1 (ref) 1 (ref)
25–29.9 1.30 (0.84–2.00) 1.22 (0.76–1.97) 1.67 (0.87–3.22) 0.49 (0.22–1.06)
≥30 1.57 (0.97–2.56) 1.32 (0.74–2.34) 1.27 (0.57–2.83) 0.81 (0.34–1.94)
Education Less than primary 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Primary education 1.14 (0.67–1.96) 1.34 (0.70–2.57) 0.69 (0.30–1.58) 1.45 (0.46–4.57)
Secondary education 0.86 (0.46–1.59) 2.27 (1.20–4.28) 0.58 (0.23–1.50) 1.93 (0.63–5.89)
University 1.41 (0.73–2.71) 2.15 (1.09–4.27) 1.29 (0.49–3.35) 2.40 (0.73–7.87)
No. of births (by each birth) 0.97 (0.85–1.10) 1.12 (0.94–1.33) –
Premenopause (ref.: postmenopause) 0.45 (0.23–0.86) 0.58 (0.22–1.49) –
Smoking No smoker 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Former smoker 1.20 (0.73–1.99) 0.91 (0.57–1.44) 0.94 (0.42–2.08) 1.66 (0.71–3.84)
Current smoker 1.72 (1.03–1.99) 0.91 (0.51–1.63) 1.33 (0.59–2.99) 0.96 (0.31–3.02)
Alcohol consumption at recruitment (g/day)
Abstainers 1 (ref) 1 (ref) 1 (ref) 1 (ref)
0–39.9 (men), 0–19.9 (women) 0.90 (0.55–1.48) 1.14 (0.59–2.19) 1.01 (0.46–2.21) 0.88 (0.27–2.81)
40–59.9 (men), 20–39.9 (women) 1.27 (0.50–3.24) 1.98 (0.83–4.73) 0.85 (0.19–3.81) 1.28 (0.27–6.08)
≥ 60 g/day (men), ≥40 g/day (women) 1.80 (0.26–12.3) 1.40 (0.46–4.31) 3.43 (0.18–64.1) 2.80 (0.50–15.6)
Alcohol when 30–40 years old
Abstainers 1 (ref) 1 (ref) 1 (ref) 1 (ref)
0–39.9 (men), 0–19.9 (women) 1.24 (0.75–2.04) 0.75 (0.39–1.41) 1.35 (0.61–2.97) 7.92 (0.95–66.0)
40–59.9 (men), 20–39.9 (women) 2.23 (0.95–5.22) 1.08 (0.49–2.37) 4.28 (1.27–14.5) 7.98 (0.84–76.2)
≥ 60 g/day (men), ≥40 g/day (women) 1.35 (0.36–5.08) 0.87 (0.40–1.89) – 3.32 (0.32–34.6)
Chronic disease involving pain
Yes (ref: No) 2.69 (1.81–4.00) 3.49 (2.33–5.21) 3.23 (1.72–6.06) 4.28 (2.10–8.71)
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use increasing from 30.2 to 40.2% and other NSAIDs
from 10.15 to 13.7%. Differences in definitions and
methodology among the studies, however, makes it diffi-
cult to compare figures from different countries.
Patterns by age and sex
Few studies reported NSAID pattern consumption by
age. Like ours, Dale et al. [23] informed of an increase in
aspirin and a decrease in other NSAIDs with age in
Norway; Sarganas et al. [17] also reported that NSAID
consumption was lower with higher age in Germany.
Clinical guidelines recommend restricting non-aspirin
NSAIDs in the older group because people at a higher
age have higher risks of NSAID-related adverse episodes,
both gastrointestinal haemorrhage and cardiovascular
events [1, 3], so our results are in accordance with this.
The interpretation of the age-pattern of aspirin is challen-
ging as its consumption would be as an analgesic/anti-in-
flammatory drug or as anti-aggregant. In our study,
aspirin was strongly associated with cardiovascular risk
factors, such as hypertension and hypercholesterolemia,
but especially with previous cardiovascular diseases, such
as acute coronary syndrome and strokes. Aspirin is
well-known as a drug able to produce gastrointestinal
haemorrhage, especially in aged people, but also for its
cardiovascular protective effects when used in low doses.
Being in no doubt of its usage for secondary prevention in
people already affected by ischemic cardiovascular disease,
current US Preventive Service Task Force [24] recom-
mendation for cardiovascular disease primary preven-
tion, however, only supports using aspirin in people
aged between 50 and 59, with possible extension on
individual basis until 69 years old, but no longer as
evidence of the risk/benefit relationship in patients
older than 70 was considered insufficient [25].
Women consumed more NSAIDs than men, as previ-
ously reported in several articles [17, 23]. In our
study, arthritis and chronic cephalalgia were more fre-
quent in women, confirming other studies which sug-
gested that non-malignant chronic diseases causing
pain are more prevalent in women [26], eventually
leading to more analgesic / anti-inflammatory usage.
Table 6 Association between cardiovascular disease or risk factors and current NSAID consumption (odds ratios and 95%
confidence intervals adjusted by age, BMI, educational level, smoking, province of recruitment and presence of arthritis, gout or
chronic cephalalgia)
NSAID Cardiovascular disease or risk factor Women Men
Non-aspirin NSAID Diabetes mellitus 1.06 (0.70–1.62) 0.59 (0.37–0.95)
Hypertension 1.02 (0.76–1.38) 0.81 (0.57–1.31)
Hypercholesterolemia 1.13 (0.86–1.47) 1.05 (0.75–1.47)
Acute coronary syndrome 0.64 (0.29–1.43) 0.86 (0.51–1.44)
Stroke 1.00 (0.58–1.13) 1.11 (0.51–2.43)
Other circulatory diseases 0.81 (0.58–1.13) 0.99 (0.63–1.58)
Propionic derivates Diabetes mellitus 1.28 (0.79–2.06) 0.56 (0.30–1.04)
Hypertension 0.94 (0.66–1.32) 0.81 (0.54–1.23)
Hypercholesterolemia 1.23 (0.90–1.66) 1.06 (0.70–1.59)
Acute coronary syndrome 1.07 (0.46–2.52) 0.63 (0.31–1.30)
Stroke 0.85 (0.32–2.22) 0.45 (0.11–1.90)
Other circulatory diseases 0.72 (0.49–1.08) 0.71 (0.38–1.35)
Aspirin Diabetes mellitus 4.36 (2.39–7.94) 2.44 (1.73–3.43)
Hypertension 4.98 (2.48–9.98) 2.44 (1.73–3.43)
Hypercholesterolemia 2.15 (1.22–3.79) 3.62 (2.58–5.07)
Acute coronary syndrome 15.2 (7.43–31.2) 11.1 (7.81–15.9)
Stroke 13.3 (6.24–28.3) 2.09 (1.19–3.66)
Other circulatory diseases 3.86 (2.16–6.90) 3.56 (2.51–5.04)
Acetic acid derivates Diabetes mellitus 0.81 (0.33–1.99) 0.95 (0.45–2.01)
Hypertension 1.39 (0.76–2.52) 1.01 (0.54–1.89)
Hypercholesterolemia 1.36 (0.78–2.35) 0.84 (0.45–1.58)
Acute coronary syndrome – 0.69 (0.26–1.84)
Stroke 1.77 (0.51–6.12) 1.75 (0.58–5.31)
Other circulatory diseases 1.53 (0.83–2.80) 0.97 (0.43–2.19)
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Education level
Education level could be used as a surrogate for
socio-economic level. It was positively associated with
NSAID use in our study. These results, however, are in
contrary to those found in Germany [7, 17] which stud-
ied education and house income as different variables with
similar findings: a positive association with NSAIDs: the
higher the education level or the higher the house income,
the more frequent the NSAID consumption is.
Health-related behaviours
Among currently smokers, we found that women had
higher ever non-aspirin NSAIDs consumption and men
had lower current non-aspirin NSAIDs current or former
smoker men had consumed more aspirin. Current alcohol
consumption had a positive but non-significant associ-
ation with non-aspirin NSAIDs. Dale et al. found a posi-
tive association of NSAID consumption with current
smoking and a negative one with alcohol [23], while both
alcohol and tobacco use were positively associated with
NSAIDs in Sweden about 20 years previously [27]. As sug-
gested in Dale et al., these differences may echo cultural
and social changes throughout that period [23].
Differences in current and ever NSAID consumption
Most patterns of consumption were quite similar for
current and ever consumers. Non-aspirin NSAIDs were
more consumed by more educated men and women,
while aspirin were more consumed by older people; these
patterns were more marked in current than in ever con-
sumers, which is probably indicating recent trends. To in-
terpret differences among current and ever consumption,
however, is speculative as data on both consumptions are
prone to different biases; in this regard, we focused more
on similarities than on differences as similar patterns
could be considered some kind of confirmatory results.
Public health implications
Recommendations for prescribing NSAIDs have been de-
veloped in guidelines [3, 4] regarding their risk profile on
gastrointestinal haemorrhage and cardiovascular episodes.
They agree in considering naproxen as being less prone to
cardiovascular episodes than ibuprofen, thus they recom-
mended using naproxen if a non-aspirin NSAID is needed
in patients with high cardiovascular risk, especially if they
are taking aspirin for cardio-protection. However, the
FDA (Food and Drug Administration), in a safety an-
nouncement for advising on cardiovascular risks associ-
ated with NSAIDs, stated there is not enough evidence to
determine that a specific non-aspirin NSAID has higher
or lower cardiovascular risk than any other [5]. Therefore,
the relevance of higher use of ibuprofen than naproxen
-as we reported- is unclear. On the other hand, older
people, which are at high risk of cardiovascular events or
gastrointestinal haemorrhage, tend to use less non-aspirin
NSAIDs and more aspirin than people at low risk. Finally,
although the higher consumption of aspirin by people
with cardiovascular diseases or risk factors would be re-
lated with its usage as secondary prevention, the fact that
the same high cardiovascular risk people did not report
lower non-aspirin NSAID consumption brings up a point
of concern because these NSAIDs could put them at
higher cardiovascular risk.
Strenghs and limitations
Our study has some limitations. Firstly, information on
NSAID use was obtained in a face-to-face interview, so it
would be affected by recall bias and social desirability bias as
well; moreover, no information was recorded on prescrip-
tions in order to validate whether the information provided
in the interview accurately represented actual NSAID con-
sumption. On the other hand, some subjects could consider
that drugs obtained over-the-counter -as occurs with many
NSAID, especially aspirin- are not really medicines, leading
to underreport their usage. Secondly, the sample is formed
by the control group in a case-control study on several types
of cancer; although participants in the study were selected at
random, some cancer cases had to be excluded. This fact
could bias the results towards lower NSAID consumption
than the general population. Thirdly, although our subjects
were selected at random, we cannot exclude that people
agreeing to participate could be self-selected because of their
health behaviours or interests, which could limit the
generalization of our results. Fourth, our data did not allow
us to distinguish whether aspirin is being taken as painkiller
or for cardiovascular prevention purposes.
By the other hand, our study has also some strengths
within his study. Firstly, we have a large sample from 12
different Spanish provinces, which makes our results
more reliable. Secondly, the vast amount of information
gathered as part of a case-control study on cancer allows
us the analysis of determinants of NSAID consumption.
It is noteworthy that participants were not aware of any
hypothesis regarding NSAID usage when they were
interviewed, which makes unlikely the presence of differ-
ential biases associated with the reported informations.
Conclusion
Summarizing, we found that propionates are the most
consumed group of NSAIDs in Spain. Consumption of
non-aspirin NSAIDs was associated with demographic
groups with lower gastrointestinal and cardiovascular
risk; however, participants at high cardiovascular risk
had no lower non-aspirin NSAID consumption, which
points out some concerns on the current NSAID con-
sumption or prescription in Spain.
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